Research and Markets: Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/h53gfr/peripheral_artery) has announced the addition of the "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Mentioned

• Alvogen Korea
• AnGes MG, Inc.
• Annexin Pharmaceuticals AB
• Apceth GmbH & Co. KG
• AstraZeneca Plc
• Athersys, Inc.
• Bayer AG
• Betagenon AB
• Cardiolynx AG
• CardioVascular BioTherapeutics, Inc.
• Celgene Corporation
• Cytokinetics, Inc.
• Diffusion Pharmaceuticals LLC
• DNAVEC Corporation
• Eli Lilly and Company
• Grifols, S.A.
• Juventas Therapeutics, Inc.
• Kowa Company, Ltd.
• Lacer, S.A.
• LTT Bio-Pharma Co., Ltd.
• MedImmune, LLC
• miRagen Therapeutics, Inc.
• Multi Gene Vascular Systems Ltd.
• Nuo Therapeutics, Inc.
• Pluristem Therapeutics Inc.
• Proteon Therapeutics, Inc.
• Recardio GmbH
• RegenoCELL Therapeutics, Inc.
• Resverlogix Corp.
• Sagene Pharmaceuticals, Inc.
• Stemedica Cell Technologies, Inc.
• Symic Biomedical, Inc.
• Theravasc, Inc.
• vasopharm GmbH
• ViroMed Co., Ltd.

For more information visit http://www.researchandmarkets.com/research/h53gfr/peripheral_artery.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005370/en/